Sharon J. Pitteri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sharon J. Pitteri has a total of 617 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Jose Garcia-Marques
Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, USA
46 shared publications Abel Bermudez
39 shared publications- Abel Bermudez
Department of Radiology, School of Medicine, Stanford University, CA 94305, USA
24 shared publications - Nicholas McIlvain Riley
Department of Chemistry, University of Washington, Seattle, WA, USA
22 shared publications - Amato J. Giaccia
Department of Oncology, University of Oxford, Oxford, UK
19 shared publications Carolyn Ruth Bertozzi
19 shared publications
Latest Publications
- Open Access
Human organoid screen links transient translational modulation to progenitor progression in corticogenesis
Human pluripotent stem cell-derived models are increasingly used to recapitulate aspects of human corticogenesis, including the emergence of diverse cortical cell types and their progression through developmental states. These systems offer an opportunity to dissect the molecular mechanisms regulating transitions between cell states, but methods for perturbing them systematically at scale remain limited. Here, we developed a semi-automated culture and high-throughput arrayed screening platform for human cortical organoids. Using a library of 1,280 small molecules designed to systematically target major signaling and regulatory pathways, we screened for modulators of EOMES , which encodes for the transcription factor TBR2, and identified Emetine, an inhibitor of translation elongation, as the top hit. The effect of Emetine on cortical cell-state progression was reproduced across human pluripotent stem cell lines, non-human primate cortical organoids, and primary human cortical tissue but not broadly across translation inhibitors. Moreover, transient exposure resulted in a shift from dividing radial glia towards cortical glutamatergic neurons. Mechanistically, nascent-proteome profiling revealed an early and coordinated remodeling of newly translated proteins that preceded detectable transcriptional changes, placing translational regulation upstream of the ensuing cell-state transition. Together, these findings highlight a role for specific translational inhibitors in promoting cortical cell-state progression and establish a scalable platform for systematic perturbation and discovery in human neural organoids.
Open AccessHuman organoid screen links transient translational modulation to progenitor progression in corticogenesis
Human pluripotent stem cell-derived models are increasingly used to recapitulate aspects of human corticogenesis, including the emergence of diverse cortical cell types and their progression through developmental states. These systems offer an opportunity to dissect the molecular mechanisms regulating transitions between cell states, but methods for perturbing them systematically at scale remain limited. Here, we developed a semi-automated culture and high-throughput arrayed screening platform for human cortical organoids. Using a library of 1,280 small molecules designed to systematically target major signaling and regulatory pathways, we screened for modulators of EOMES , which encodes for the transcription factor TBR2, and identified Emetine, an inhibitor of translation elongation, as the top hit. The effect of Emetine on cortical cell-state progression was reproduced across human pluripotent stem cell lines, non-human primate cortical organoids, and primary human cortical tissue but not broadly across translation inhibitors. Moreover, transient exposure resulted in a shift from dividing radial glia towards cortical glutamatergic neurons. Mechanistically, nascent-proteome profiling revealed an early and coordinated remodeling of newly translated proteins that preceded detectable transcriptional changes, placing translational regulation upstream of the ensuing cell-state transition. Together, these findings highlight a role for specific translational inhibitors in promoting cortical cell-state progression and establish a scalable platform for systematic perturbation and discovery in human neural organoids.
- Open Access
- 21 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
Deep Intact Glycoproteomic Analysis Reveals Multi-Level Glycosylation Heterogeneity in Renal Tumors
- 21 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
Open AccessDeep Intact Glycoproteomic Analysis Reveals Multi-Level Glycosylation Heterogeneity in Renal Tumors
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Osteosarcoma, the most common primary bone malignancy in adolescents and young adults, is still marked by poor long-term survival and high mortality. Although immune checkpoint blockade (ICB) has transformed treatment for several cancers, its benefit in osteosarcoma has been minimal, largely due to osteosarcoma’s “immune-cold” phenotype characterized by scarce tumor-infiltrating lymphocytes. Novel strategies are urgently needed to overcome this resistance. Y-box binding protein 1 (YB-1), a pro-oncogenic member of the cold-shock protein superfamily, represents a promising target to sensitize osteosarcoma to ICB. In this study, we evaluate SU056, a small-molecule YB-1 inhibitor, which both suppressed intrinsic osteosarcoma tumor growth and remodeled the tumor microenvironment. SU056 treatment markedly reduced immunosuppressive populations, including regulatory T cells and M2-polarized tumor-associated macrophages, while enhancing the infiltration of granzyme B-positive cytotoxic CD8+ T and NK cells. Combination therapy with SU056 and anti–PD-1 blockade produced superior tumor growth inhibition and significantly prolonged survival compared with either monotherapy. These findings highlight SU056 as a potent immunomodulatory agent and support its coadministration with ICB as a promising therapeutic approach for osteosarcoma.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Osteosarcoma, the most common primary bone malignancy in adolescents and young adults, is still marked by poor long-term survival and high mortality. Although immune checkpoint blockade (ICB) has transformed treatment for several cancers, its benefit in osteosarcoma has been minimal, largely due to osteosarcoma’s “immune-cold” phenotype characterized by scarce tumor-infiltrating lymphocytes. Novel strategies are urgently needed to overcome this resistance. Y-box binding protein 1 (YB-1), a pro-oncogenic member of the cold-shock protein superfamily, represents a promising target to sensitize osteosarcoma to ICB. In this study, we evaluate SU056, a small-molecule YB-1 inhibitor, which both suppressed intrinsic osteosarcoma tumor growth and remodeled the tumor microenvironment. SU056 treatment markedly reduced immunosuppressive populations, including regulatory T cells and M2-polarized tumor-associated macrophages, while enhancing the infiltration of granzyme B-positive cytotoxic CD8+ T and NK cells. Combination therapy with SU056 and anti–PD-1 blockade produced superior tumor growth inhibition and significantly prolonged survival compared with either monotherapy. These findings highlight SU056 as a potent immunomodulatory agent and support its coadministration with ICB as a promising therapeutic approach for osteosarcoma.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 1 shows that the effect of SU056 is dependent on YB-1.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 1 shows that the effect of SU056 is dependent on YB-1.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 2 shows that SU056 does not alter the glycolytic rate of U2OS cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 2 shows that SU056 does not alter the glycolytic rate of U2OS cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 4 shows representative dot plots of CD4+ and CD8+ expression in control and SU056-treated mice.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 4 shows representative dot plots of CD4+ and CD8+ expression in control and SU056-treated mice.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 3 shows that SU056 sensitized 143B and U2OS cells to doxorubicin.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 3 shows that SU056 sensitized 143B and U2OS cells to doxorubicin.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 5 shows bar graphs representing PD1+ or PDL1+ expression in immune populations following SU056 treatment.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression
Supplemental Fig. 5 shows bar graphs representing PD1+ or PDL1+ expression in immune populations following SU056 treatment.
- 25 July 2026
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
Quantifying Protein Temporal Changes with Mass Spectrometry in Plasma Samples from Breast Cancer Patients Undergoing Radiotherapy
Radiation therapy (RT) is a central component of cancer treatment, including breast cancer, and primarily damages DNA in cancer cells, causing cell death. However, secondary effects of RT that may influence tumor and normal tissue both within and beyond the site of irradiation are not well characterized, particularly at the level of the circulating blood proteome. In this study, isotopic acrylamide labeling of proteins and high-resolution LC–MS/MS were used to analyze plasma proteins from breast cancer patients before, during, and after RT. Clustering analysis was used to group proteins according to how their levels changed over time. A total of 31 proteins were identified whose levels were altered during RT but returned to baseline following the conclusion of treatment, representing key parts of the immune response to RT. Another set of 31 proteins related to the extracellular matrix and other functions was altered during RT and remained altered after RT. Specific time points were also examined, and acute changes were identified at the start of RT in the levels of 63 proteins involved in coagulation, cell–cell adhesion, and carbohydrate metabolism. After the end of RT, the circulating levels of 23 extracellular matrix proteins remained altered. These LC–MS/MS findings were validated orthogonally by ELISAs of three proteins in a larger group of breast cancer patients undergoing RT. Overall, in this study, temporal changes in the circulating blood proteome of breast cancer patients undergoing RT were characterized, and these altered protein levels were linked to potential alterations in biological pathways.
- 25 July 2026
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
Quantifying Protein Temporal Changes with Mass Spectrometry in Plasma Samples from Breast Cancer Patients Undergoing Radiotherapy
Radiation therapy (RT) is a central component of cancer treatment, including breast cancer, and primarily damages DNA in cancer cells, causing cell death. However, secondary effects of RT that may influence tumor and normal tissue both within and beyond the site of irradiation are not well characterized, particularly at the level of the circulating blood proteome. In this study, isotopic acrylamide labeling of proteins and high-resolution LC–MS/MS were used to analyze plasma proteins from breast cancer patients before, during, and after RT. Clustering analysis was used to group proteins according to how their levels changed over time. A total of 31 proteins were identified whose levels were altered during RT but returned to baseline following the conclusion of treatment, representing key parts of the immune response to RT. Another set of 31 proteins related to the extracellular matrix and other functions was altered during RT and remained altered after RT. Specific time points were also examined, and acute changes were identified at the start of RT in the levels of 63 proteins involved in coagulation, cell–cell adhesion, and carbohydrate metabolism. After the end of RT, the circulating levels of 23 extracellular matrix proteins remained altered. These LC–MS/MS findings were validated orthogonally by ELISAs of three proteins in a larger group of breast cancer patients undergoing RT. Overall, in this study, temporal changes in the circulating blood proteome of breast cancer patients undergoing RT were characterized, and these altered protein levels were linked to potential alterations in biological pathways.
- Top Cited Papers
- 16 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6808) , eaea3075
Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging
Aging disrupts tissue homeostasis across organ systems. Here, we identify tissue-resident macrophages (TRMs) as central coordinators of age-related organ decline through impaired clearance of senescent neutrophils, a process regulated by the immunomodulatory prostaglandin E2 (PGE 2 ) receptor EP2. Reducing TRM EP2 signaling in aged mice preserved youthful mitochondrial fitness and prevented cognitive decline, frailty, sarcopenia, adiposity, cardiac impairment, and systemic inflammation. Plasma proteomics implicated the liver as a major source of age-associated immune change, in which reduced TRM EP2 signaling rescued neutrophil efferocytosis and prevented paracrine stress in neighboring cells. Elevated TRM EP2 expression and senescent neutrophils were also observed in aged and diseased human tissues. Pharmacologic EP2 inhibition restored youthful neutrophil clearance, establishing impaired TRM efferocytosis as a reversible driver of organ decline in aging.
- 16 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6808) , eaea3075
Top Cited PapersRestored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging
Aging disrupts tissue homeostasis across organ systems. Here, we identify tissue-resident macrophages (TRMs) as central coordinators of age-related organ decline through impaired clearance of senescent neutrophils, a process regulated by the immunomodulatory prostaglandin E2 (PGE 2 ) receptor EP2. Reducing TRM EP2 signaling in aged mice preserved youthful mitochondrial fitness and prevented cognitive decline, frailty, sarcopenia, adiposity, cardiac impairment, and systemic inflammation. Plasma proteomics implicated the liver as a major source of age-associated immune change, in which reduced TRM EP2 signaling rescued neutrophil efferocytosis and prevented paracrine stress in neighboring cells. Elevated TRM EP2 expression and senescent neutrophils were also observed in aged and diseased human tissues. Pharmacologic EP2 inhibition restored youthful neutrophil clearance, establishing impaired TRM efferocytosis as a reversible driver of organ decline in aging.